blue cross blue shield plans reverse course on glp-1 coverage Why we are changing of drugs for weight loss Blue Cross Blue Shield plans

Methods Retrospective study utilizing data from a federated research network (TriNetX)

10.1016/j.prnil.2022.11.003 90 KitaharaC

This study, which included around 6,400 patients, employed Cox regression analysis and confirmed that diabetic patients using GLP-1R agonistssuch as exenatide, liraglutide, dulaglutide, and semaglutide were less likely to receive a new glaucoma diagnosis (76)

Decisions about GLP-1 therapy should be made in partnership with a licensed healthcare provider who can evaluate your individual health history and goals.

Weight loss represents a significant secondary goal alongside diabetes management for many who select this option